A randomized autologous ATA190 study in progressive MS patients
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs ATA-190 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 07 Nov 2019 According to an Atara Biotherapeutics media release, the company will not initiate a randomized study of autologous ATA190 in progressive MS at this time and will evaluate strategic options for this program. The company's decision is based on continued encouraging ATA188 results, acceleration of the ATA188 randomized Phase 1b study and the Company's strategic focus on off-the-shelf, allogeneic T-cell immunotherapies.
- 09 May 2019 According to an Atara Biotherapeutics media release, the company expected to initiate this study in the second half of 2019.
- 08 Aug 2018 New trial record